Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.

Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions

Abstract

Interventions that have even quite modest effects at the individual level could drastically reduce the future burden of dementia associated with Alzheimer's disease at the population level. In the past three decades, both pharmacological and lifestyle interventions have been studied for the prevention of cognitive decline or dementia in randomised controlled trials of individuals mostly aged older than 50-55 years with or without risk factors for Alzheimer's disease. Several trials testing the effects of physical activity, cognitive training, or antihypertensive interventions showed some evidence of efficacy on a primary cognitive endpoint. However, most of these trials had short follow-up periods, and further evidence is needed to confirm effectiveness and establish the optimum design or dose of interventions and ideal target populations. Important innovations in ongoing trials include the development of multidomain interventions, and the use of biomarker or genetic inclusion criteria. Challenges include the use of adaptive trial designs, the development of standardised, sensitive outcome measures, and the need for interventions that can be implemented in resource-poor settings.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(15)00153-2

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 149 references

Cited by

See all 316

Metadata

Authors
Andrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B.
Affiliations
  • Université Toulouse III - Paul Sabatier (FR)
  • University of Oxford (GB)
  • University of Southern California (US)
Corresponding author
Andrieu, Sandrine
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2015-09
Volume
14
Issue
9
Pages
926-944
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2112483965
Cited by
293
References
149
Citations by year
2026: 6 · 2025: 25 · 2024: 21 · 2023: 18 · 2022: 30 · 2021: 34 · 2020: 24 · 2019: 31 · 2018: 37 · 2017: 27 · 2016: 36 · 2015: 4
FWCI
4.78
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute for Health and Care Research (NF-SI-0512-10053)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Cognitive Abilities and Testing
Keywords
Alzheimer's disease prevention, dementia prevention, cognitive decline, physical activity, cognitive training, antihypertensive drugs, multidomain intervention, biomarkers, adaptive trial design, outcome measures, resource-limited settings, dementia burden
MeSH terms
Alzheimer Disease, Antioxidants, Clinical Trials as Topic, Forecasting, Humans, Learning, Risk Factors, Risk Reduction Behavior

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. https://app.cochat.ai/papers/10.1016/s1474-4422(15)00153-2
The paper
Andrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015). Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(15)00153-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.